Stanley-Laman Group’s iShares Biotechnology ETF IBB Stock Holding History

Stanley-Laman Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,006	Closed	-$237K	–	295
2014 Q1	$237K	Sell	3,006 -1,740	-37%	-$145K	0.04%	292
2013 Q4	$359K	Buy	+4,746	New	+$337K	0.08%	158

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Stanley-Laman Group's IBB Position: Q2 2014 in Review

Stanley-Laman Group sold out of iShares Biotechnology ETF (IBB) in Q2 2014, closing a stake of 3,006 shares — an estimated $237K sold.

Stanley-Laman Group first reported a position in IBB in Q4 2013 and held it in 2 quarters. The position peaked at $359K in Q4 2013. 307 funds tracked by Wall St. Rank hold IBB as of Q2 2014.

Stanley-Laman Group reported no remaining iShares Biotechnology ETF position as of Q2 2014 after selling out during the quarter.
Stanley-Laman Group sold 3,006 iShares Biotechnology ETF shares in Q2 2014, an estimated $237K.
Stanley-Laman Group first reported a position in iShares Biotechnology ETF in Q4 2013 and held it in 2 quarters.
Stanley-Laman Group's iShares Biotechnology ETF position peaked at $359K in Q4 2013.
307 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2014.

Based on Stanley-Laman Group's 13F filing for Q2 2014, filed 2 Jul 2014.